Brainstorm Cell Therapeutics Inc. (BCLI) Dividend History

Company News

• Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement

  Brainstorm Cell Therapeutics voluntarily delisted from Nasdaq due to non-compliance with shareholder equity requirements, with stock price dropping 42.74%. The company will continue trading on OTCQB Venture Market and remains committed to developing NurOwn therapy for ALS.

  Benzinga
• Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight

  The cell and gene therapies in rare disorders market is expected to grow significantly by 2034, driven by an increase in approvals and adoption of these treatments, ability to treat a broad array of conditions, and rising prevalence of rare disorders.

  GlobeNewswire Inc.

  Featured Companies: ABEO CAPR EDIT FDMT FOLD OCGN PFE RARE RGNX SGMO
• Creating a Profitable Penny Stocks Watchlist

  Here's how to create a profitable penny stocks watchlist The post Creating a Profitable Penny Stocks Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: VVOS
• FDA panel rejects ALS treatment from Brainstorm Cell Therapeutics

  A U.S. Food and Drug Administration advisory committee voted against a treatment from BrainStorm Cell Therapeutics for amyotrophic lateral sclerosis, or ALS.

  MarketWatch
• Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More

  Pipeline updates from MACK and MRNA are the key highlights from the biotech sector during the past week.

  Zacks Investment Research

  Featured Companies: MRNA